Welcome to BioSeeker Group!

Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Additional Information

Published Date Jul 12, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1323
PDF Fact Sheet View Fact Sheet for the report Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market.

    To find out more about Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. BioSeeker has applied its unique drug assessment methodology to stratify the lung cancer pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of lung cancer drugs is split between the 43% which have unique drug target strategies and the other part which have head-to-head target competing lung cancer drugs in 58 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lung cancer drugs in general. Contributing to this fact is heavily utilized drug target strategies like: TUBB, TOP2A and TOP1.

* Nine out of ten drug target strategies in Phase II development are new to lung cancer drugs and the greatest numbers of new target strategies are found in Phase II (39%) and Phase I development (17%).

* Small molecules, antibodies and reformulated drugs are the dominating compound strategies of lung cancer drugs, which represent almost 80% of the entire pipeline. Cell therapy based lung cancer drugs has the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lung cancer drugs.

* Peptide based lung cancer drugs has a 50% drug target strategy overlap with all other compound strategies, especially with that of antibodies, small molecules and reformulated compound strategies.


* The highest number of described drug target strategies of lung cancer drugs belongs to Pfizer (15), Bristol-Myers Squibb (11) and Hoffmann-La Roche (11).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lung cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 22
4.2 List of Tables 22
5 Introduction 31
5.1 The Scope of this Report 31
5.2 Definitions 34
5.3 Abbreviations 34
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 35
6.1 Drug Repositioning in Oncology 35
6.2 Introduction to Targets of Lung Cancer Drugs 36
6.2.1 Auxiliary Transport Protein Activity Targets 44
6.2.2 Carboxy-lyase Activity Targets 45
6.2.3 Catalytic Activity Targets 46
6.2.4 Cell Adhesion Molecule Activity Targets 52
6.2.5 Chaperone Activity Targets 63
6.2.6 Chemokine Activity Targets 67
6.2.7 Complement Activity Targets 70
6.2.8 Cysteine-type Peptidase Activity Targets 71
6.2.9 Cytokine Activity Targets 78
6.2.10 DNA Binding Targets 87
6.2.11 DNA Repair Protein Targets 90
6.2.12 DNA Topoisomerase Activity Targets 93
6.2.13 DNA-directed DNA Polymerase Activity Targets 99
6.2.14 DNA-methyltransferase Activity Targets 106
6.2.15 Extracellular Ligand-gated Ion Channel Activity Targets 107
6.2.16 Extracellular Matrix Structural Constituent Targets 109
6.2.17 G-protein Coupled Receptor Activity Targets 112
6.2.18 Glutathione Transferase Activity Targets 122
6.2.19 Growth Factor Activity Targets 124
6.2.20 GTPase Activity Targets 138
6.2.21 Hormone Activity Targets 147
6.2.22 Hydrolase Activity Targets 149
6.2.23 Intracellular Ligand-gated Ion Channel Activity Targets 150
6.2.24 Ion Channel Activity Targets 151
6.2.25 Kinase Activity Targets 152
6.2.26 Kinase Binding Targets 163
6.2.27 Kinase Regulator Activity Targets 164
6.2.28 Ligand-dependent Nuclear Receptor Activity Targets 167
6.2.29 Ligase Activity Targets 173
6.2.30 Lipid Kinase Activity Targets 180
6.2.31 Lipid Phosphatase Activity Targets 188
6.2.32 Metallopeptidase Activity Targets 189
6.2.33 Molecular Function Unknown Targets 194
6.2.34 Motor Activity Targets 202
6.2.35 Oxidoreductase Activity Targets 204
6.2.36 Peptidase Activity Targets 209
6.2.37 Peroxidase Activity Targets 219
6.2.38 Phosphoric Diester Hydrolase Activity Targets 220
6.2.39 Protein Binding Targets 223
6.2.40 Protein Serine/Threonine Kinase Activity Targets 228
6.2.41 Protein Threonine/Tyrosine Kinase Activity Targets 259
6.2.42 Protein Threonine/Tyrosine Kinase Activity Targets 264
6.2.43 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 265
6.2.44 Protein-tyrosine Kinase Activity Targets 266
6.2.45 Receptor Activity Targets 279
6.2.46 Receptor Binding Targets 302
6.2.47 Receptor Signaling Complex Scaffold Activity Targets 310
6.2.48 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 315
6.2.49 RNA Binding Targets 317
6.2.50 RNA-directed DNA Polymerase Activity Targets 318
6.2.51 Serine-type Peptidase Activity Targets 320
6.2.52 Structural Constituent of Cytoskeleton Targets 324
6.2.53 Structural Molecule Activity Targets 328
6.2.54 Transcription Factor Activity Targets 330
6.2.55 Transcription Regulator Activity Targets 360
6.2.56 Transferase Activity Targets 368
6.2.57 Translation Regulator Activity Targets 370
6.2.58 Transmembrane Receptor Activity Targets 376
6.2.59 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 380
6.2.60 Transporter Activity Targets 422
6.2.61 Ubiquitin-specific Protease Activity Targets 430
6.2.62 Other Targets 432
6.3 The Cancer Genome Project and Targets of Lung Cancer Drugs 434
6.3.1 Targets of Lung Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 434
6.4 Structure-based Drug Design in Lung Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 441
6.5 Target-Target Interactions among Identified Targets of Lung Cancer Drugs 446
6.6 The Drug-Target Competitive Landscape 451
6.7 Protein Expression Levels of Identified Targets of Lung Cancer Drugs 456
6.8 Pathway Assessment of Lung Cancer Drugs 459
6.8.1 Tools for Analysis of Cancer Pathways 460
6.8.2 Pathway Assessment 461
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development 527
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Lung Cancer Drugs 531
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 533
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 536
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 544
7.5 Preclinical Development: New and Unique Drug Target Strategies of Lung Cancer Drugs 549
7.6 Drug Target Strategies of Suspended or Terminated Lung Cancer Drugs 553
7.7 Target Strategy Development Profiles of Lung Cancer Drugs 558
7.7.1 Marketed 564
7.7.2 Phase III 579
7.7.3 Phase II 599
7.7.4 Phase I 693
7.7.5 Preclinical 733
7.7.6 Suspended 763
7.7.7 Ceased 766
7.8 The Competition Through Close Mechanistic Approximation of Lung Cancer Drugs 809
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy 818
8.1 Small Molecules 820
8.1.1 Background 820
8.1.2 Target Strategies of Small Molecule Drugs 821
8.2 Peptide & Protein Drugs 835
8.2.1 Background 835
8.2.2 Target Strategies of Peptide and Protein Drugs 836
8.3 Antibodies 842
8.3.1 Background 842
8.3.2 Target Strategies of Antibody Drugs 842
8.4 Nucleic Acid Therapies 848
8.4.1 Background 848
8.4.2 Target Strategies of Nucleic Acid Drugs 849
8.5 Cell & Gene Therapy 852
8.5.1 Background 852
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 853
8.6 Drug Delivery and Nanotechnology 858
8.6.1 Background 858
8.6.2 Target Strategies of Reformulated Drugs 858
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 862
9 Selecting Subindication for Lung Cancer Drugs 871
9.1 NSCLC 872
9.2 SCLC 889
9.3 Lung Cancer (LC) 894
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator 899
10.1 Competitive Fall-Out Assessment 899
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 901
10.3 A&G Pharmaceutical 902
10.4 Abbott 903
10.5 Active Biotech 906
10.6 Adherex 907
10.7 Advanomics 908
10.8 Advantagene 910
10.9 AEgera 911
10.10 AEterna Zentaris 912
10.11 Agennix 913
10.12 Aida Pharmaceuticals 914
10.13 Alchemia 915
10.14 Alder Biopharmaceuticals 917
10.15 Alethia Biotherapeutics 918
10.16 Allos Therapeutics 919
10.17 AlphaVax 920
10.18 Altor BioScience 921
10.19 Amgen 922
10.20 AngioChem 928
10.21 Antisense Pharma 930
10.22 Antisoma 931
10.23 Anza Therapeutics 932
10.24 ApopLogic Pharmaceuticals 933
10.25 Apotex 935
10.26 Ariad 936
10.27 ArQule 938
10.28 Array BioPharma 940
10.29 Ascenta Therapeutics 942
10.30 Astellas 943
10.31 AstraZeneca 946
10.32 AVEO 951
10.33 Avila Therapeutics 952
10.34 Axelar 954
10.35 Bayer 955
10.36 Benitec 959
10.37 Betapharma 960
10.38 Biogen Idec 962
10.39 Biokine Therapeutics 965
10.40 BioLineRx 966
10.41 BioNumerik 967
10.42 BioSante 969
10.43 Boehringer Ingelheim 970
10.44 Bristol-Myers Squibb 973
10.45 BTG 984
10.46 Calando Pharmaceuticals 986
10.47 CanBas 987
10.48 Celator Pharmaceuticals 988
10.49 Celgene 990
10.50 Cell Therapeutics 993
10.51 Celtic Pharma 996
10.52 Center of Molecular Immunology 997
10.53 Cephalon 999
10.54 CG Therapeutics 1002
10.55 Chemokine Therapeutics 1003
10.56 Chong Kun Dang 1004
10.57 Circadian Technologies 1007
10.58 Clavis Pharma 1008
10.59 CLL Pharma 1009
10.60 Coronado Biosciences 1012
10.61 Critical Outcome Technologies 1014
10.62 Curaxis 1015
10.63 Curis 1016
10.64 Cyclacel 1018
10.65 Cynvec 1019
10.66 CytImmune Sciences 1020
10.67 Cytokinetics 1021
10.68 CytRx 1023
10.69 Daiichi Sankyo 1025
10.70 Dainippon Sumitomo Pharma 1030
10.71 Dara Biosciences 1033
10.72 Dendreon 1034
10.73 Dong-A 1036
10.74 ECI 1038
10.75 Eisai 1039
10.76 Elara Pharmaceuticals 1043
10.77 Eli Lilly 1046
10.78 Endocyte 1052
10.79 EntreMed 1054
10.80 EpiCept 1055
10.81 Exelixis 1057
10.82 Fresenius 1062
10.83 Galapagos 1064
10.84 Gemin X Biotechnologies 1065
10.85 Genmab 1066
10.86 Genta 1068
10.87 GenVec 1069
10.88 Genzyme 1070
10.89 Geron 1071
10.90 Gilead Sciences 1073
10.91 GlaxoSmithKline 1075
10.92 GlobeImmune 1079
10.93 GlycoGenesys 1080
10.94 Gradalis 1081
10.95 Hanmi 1082
10.96 Hoffmann-La Roche 1083
10.97 Human Genome Sciences 1091
10.98 Idera Pharmaceuticals 1092
10.99 ImmunoCellular Therapeutics 1093
10.100 Immunocore 1094
10.101 ImmunoGen 1096
10.102 Immunomedics 1099
10.103 ImmuPharma 1103
10.104 Incyte Corporation 1104
10.105 Infinity Pharmaceuticals 1105
10.106 Innovive 1106
10.107 Inovio 1107
10.108 Insys Therapeutics 1108
10.109 Intezyne Technologies 1111
10.110 Introgen Therapeutics 1113
10.111 Ipsen 1115
10.112 Isis Pharmaceuticals 1117
10.113 Jennerex Biotherapeutics 1119
10.114 Johnson & Johnson 1120
10.115 Kiadis 1123
10.116 Kyowa Hakko Kirin 1124
10.117 Ligand 1128
10.118 Lorus Therapeutics 1129
10.119 MacroGenics 1131
10.120 Marillion Pharmaceuticals 1132
10.121 Meda 1133
10.122 MediGene 1134
10.123 Medisyn Technologies 1136
10.124 Menarini 1138
10.125 Merck & Co 1140
10.126 Merck KGaA 1143
10.127 Merrimack 1147
10.128 Mersana Therapeutics 1148
10.129 MethylGene 1150
10.130 Micromet 1152
10.131 Mirna Therapeutics 1154
10.132 MolMed 1155
10.133 Mologen 1157
10.134 Mycenax 1159
10.135 Nektar Therapeutics 1160
10.136 Nereus Pharmaceuticals 1162
10.137 Nerviano Medical Sciences 1163
10.138 Neurocrine Biosciences 1165
10.139 NewSouth Innovations 1166
10.140 Nippon Kayaku 1167
10.141 Nippon Shinyaku 1169
10.142 Non-industrial Source 1170
10.143 Novacea 1171
10.144 Novartis 1172
10.145 Oasmia 1178
10.146 OncoGenex Pharmaceuticals 1180
10.147 OncoMed 1182
10.148 Oncothyreon 1183
10.149 Orchestra Therapeutics 1185
10.150 OSI Pharmaceuticals 1186
10.151 OXiGENE 1189
10.152 Paladin Labs 1190
10.153 PanaGin 1191
10.154 PBL Therapeutics 1192
10.155 Pfizer 1193
10.156 Pharmacyclics 1202
10.157 PharmaGap 1203
10.158 PharmaMar 1204
10.159 Pharmexa 1207
10.160 Philogen 1208
10.161 Pierre Fabre 1210
10.162 Pro-Pharmaceuticals 1211
10.163 Progen Pharmaceuticals 1212
10.164 Receptor BioLogix 1213
10.165 Regeneron 1214
10.166 Regulon 1215
10.167 RESprotect 1216
10.168 Rexahn 1217
10.169 Rigel 1219
10.170 Samyang 1221
10.171 Sanofi-Aventis 1225
10.172 Sareum 1229
10.173 Seattle Genetics 1231
10.174 ShimodaAtlantic Oncology 1232
10.175 Shire 1233
10.176 Sigma-Tau 1234
10.177 Silence Therapeutics 1236
10.178 Simcere Pharmaceuticals 1237
10.179 Sirnaomics 1238
10.180 SRI International 1239
10.181 SuperGen 1240
10.182 Supratek Pharma 1243
10.183 Switch Pharma 1247
10.184 Symphogen 1248
10.185 SynDevRx 1249
10.186 Synta Pharmaceuticals 1251
10.187 Taiho 1252
10.188 Takeda 1254
10.189 Talon Therapeutics 1256
10.190 Tapestry Pharmaceuticals 1257
10.191 Taxolog 1259
10.192 Tekmira Pharmaceuticals 1262
10.193 Telik 1264
10.194 Thallion Pharmaceuticals 1265
10.195 Therion Biologics 1266
10.196 Theryte 1267
10.197 Titan Pharmaceuticals 1268
10.198 TopoTarget 1270
10.199 Tracon Pharmaceuticals 1271
10.200 Tragara Pharmaceuticals 1272
10.201 Transgene 1273
10.202 TriAct Therapeutics 1275
10.203 Trion Pharma 1276
10.204 UCB 1277
10.205 Valeant 1278
10.206 Vaxon Biotech 1279
10.207 VaxOnco 1280
10.208 Vernalis 1281
10.209 Vertex Pharmaceuticals 1282
10.210 Vical 1283
10.211 Vion Pharmaceuticals 1284
10.212 VioQuest Pharmaceuticals 1286
10.213 Wilex 1287
10.214 Wyeth 1288
10.215 Xerion 1289
10.216 Xoma 1291
10.217 Yakult Honsha 1292
10.218 YM BioSciences 1294
10.219 Zhejiang Beta Pharma 1296
10.220 Zivena 1298
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Lung Cancer Drugs 450
Figure 2: The Drug-Target Competitive Landscape of Lung Cancer Drugs - Large Cluster 452
Figure 3: The Drug-Target Competitive Landscape Lung Cancer Drugs - Smaller Clusters 453
Figure 4: Head-to-Head Targeting Competitive Landscape of Lung Cancer Drugs - Large Clusters 454
Figure 5: Head-to-Head Targeting Competitive Landscape of Lung Cancer Drugs - Smaller Clusters 455
Figure 6: Distribution of Compound Strategies among Lung Cancer Drugs 862
Figure 7: Primary Sub-cellular Localization of Drug Targets 863

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Lung Cancer Drug Pipeline by Stage of Development 31
Table 3: Head to Head Target Competition among Lung Cancer Drugs 31
Table 4: Overview of Drug Target Strategy Themes 36
Table 5: Terminally Ceased Targets of Lung Cancer Drugs 37
Table 6: Official Gene Name to Target Profle 38
Table 7: Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 435
Table 8: Identity of Lung Cancer Drug Targets with Available Biological Structures 441
Table 9: Number of Target-Target Interactions among Targets of Lung Cancer Drugs 447
Table 10: Available Protein Expression Profiles of Lung Cancer Drugs Targets 456
Table 11: Pathway Summary 461
Table 12: Drug Targets without any Identified Assigned Pathways 461
Table 13: Pathway Profiles According to BioCarta of Lung Cancer Drug Targets 463
Table 14: Pathway Profiles According to KEGG of Lung Cancer Drug Targets 489
Table 15: Pathway Profiles According to NetPath of Lung Cancer Drug Targets 518
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 527
Table 17: Top Competitive Target Strategies of Lung Cancer Drugs 528
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Lung Cancer Drugs 531
Table 19: The Competition Through Close Mechanistic Approximation Between Lung Cancer Drugs being Marketed or in Pre-registration 532
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Lung Cancer Drugs 533
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Lung Cancer Drugs 534
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Lung Cancer Drugs 536
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs 541
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Lung Cancer Drugs 544
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs 547
Table 26: New and Unique Target Strategies in Preclinical Development of Lung Cancer Drugs 549
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Lung Cancer Drugs 551
Table 28: Target Strategies of Suspended and Terminated Lung Cancer Drugs 553
Table 29: Connecting Target Strategy with Its Profile Identification Number 558
Table 30: The Competition Through Close Mechanistic Approximation Among Lung Cancer Drugs 809
Table 31: Overview of Compound Strategy Competition Among Lung Cancer Drugs 819
Table 32: Overview of the Competitive Landscape of Small Molecule Based Lung Cancer Drugs 821
Table 33: Competitive Comparison of Target Strategies of Small Molecule Lung Cancer Drugs 822
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Lung Cancer Drugs 827
Table 35: Overview of the Competitive Landscape of Peptide Based Lung Cancer Drugs 836
Table 36: Competitive Comparison of Target Strategies of Peptide Based Lung Cancer Drugs 837
Table 37: Pursued Target Strategies of Peptide Based Lung Cancer Drugs 837
Table 38: Overview of the Competitive Landscape of Protein Based Lung Cancer Drugs 839
Table 39: Competitive Comparison of Target Strategies of Protein Based Lung Cancer Drugs 840
Table 40: Pursued Target Strategies of Protein Based Lung Cancer Drugs 840
Table 41: Overview of the Competitive Landscape of Antibody Based Lung Cancer Drugs 842
Table 42: Competitive Comparison of Target Strategies of Antibody Based Lung Cancer Drugs 843
Table 43: Pursued Target Strategies of Antibody Based Lung Cancer Drugs 845
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Lung Cancer Drugs 849
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Lung Cancer Drugs 850
Table 46: Pursued Target Strategies of Nucleic Acid Based Lung Cancer Drugs 850
Table 47: Potential Forms of Cell Therapy 852
Table 48: Vectors in Gene Therapy 853
Table 49: Overview of the Competitive Landscape of Cell Therapy Based Lung Cancer Drugs 853
Table 50: Pursued Target Strategies of Cell Therapy Based Lung Cancer Drugs 854
Table 51: Overview of the Competitive Landscape of Gene Therapy Based Lung Cancer Drugs 855
Table 52: Competitive Comparison of Target Strategies of Gene Therapy Based Lung Cancer Drugs 856
Table 53: Pursued Target Strategies of Gene Therapy Based Lung Cancer Drugs 856
Table 54:Overview of the Competitive Landscape of Reformulated Lung Cancer Drugs 858
Table 55: Competitive Comparison of Target Strategies of Reformulated Lung Cancer Drugs 859
Table 56: Pursued Target Strategies of Reformulated Lung Cancer Drugs 860
Table 57: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 863
Table 58 Competitive Summary by Subindication of Lung Cancer Drugs 871
Table 59: Target Strategy Development Profiles of Drugs for the Treatment of NSCLC 872
Table 60: The Competition through Close Mechanistic Approximation between NSCLC Drugs 882
Table 61: Target Strategy Development Profiles of Drugs for the Treatment of SCLC 889
Table 62: The Competition through Close Mechanistic Approximation between SCLC Drugs 892
Table 63: Target Strategy Development Profiles of Drugs for the Treatment of Lung Cancer (LC) 894
Table 64: The Competition through Close Mechanistic Approximation between Lung Cancer (LC) Drugs 897
Table 65: Example of a Competitive Fall-Out Table (Targeting TUBB) 900
Table 66: Summary Table of Corporate Changes in the Competitive Landscape of Lung Cancer Drug Development 901
Table 67: A&G Pharmaceutical’s Included Lung Cancer Pipeline and Competitive Fall-Out 902
Table 68: Abbott’s Included Lung Cancer Pipeline and Competitive Fall-Out 903
Table 69: Active Biotech’s Included Lung Cancer Pipeline and Competitive Fall-Out 906
Table 70: Adherex’s Included Lung Cancer Pipeline and Competitive Fall-Out 907
Table 71: Advanomics’Included Lung Cancer Pipeline and Competitive Fall-Out 908
Table 72: Advantagene’s Included Lung Cancer Pipeline and Competitive Fall-Out 910
Table 73: AEgera’s Included Lung Cancer Pipeline and Competitive Fall-Out 911
Table 74: AEterna Zentaris’Included Lung Cancer Pipeline and Competitive Fall-Out 912
Table 75: Agennix’s Included Lung Cancer Pipeline and Competitive Fall-Out 913
Table 76: Aida Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 914
Table 77: Alchemia’s Included Lung Cancer Pipeline and Competitive Fall-Out 915
Table 78: Alder Biopharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 917
Table 79: Alethia Biotherapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 918
Table 80: Allos Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 919
Table 81: AlphaVax’s Included Lung Cancer Pipeline and Competitive Fall-Out 920
Table 82: Altor BioScience’s Included Lung Cancer Pipeline and Competitive Fall-Out 921
Table 83: Amgen’s Included Lung Cancer Pipeline and Competitive Fall-Out 922
Table 84: AngioChem’s Included Lung Cancer Pipeline and Competitive Fall-Out 928
Table 85: Antisense Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 930
Table 86: Antisoma’s Included Lung Cancer Pipeline and Competitive Fall-Out 931
Table 87: Anza Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 932
Table 88: ApopLogic Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 933
Table 89: Apotex’s Included Lung Cancer Pipeline and Competitive Fall-Out 935
Table 90: Ariad’s Included Lung Cancer Pipeline and Competitive Fall-Out 936
Table 91: ArQule’s Included Lung Cancer Pipeline and Competitive Fall-Out 938
Table 92: Array BioPharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 940
Table 93: Ascenta Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 942
Table 94: Astellas’Included Lung Cancer Pipeline and Competitive Fall-Out 943
Table 95: AstraZeneca’s Included Lung Cancer Pipeline and Competitive Fall-Out 946
Table 96: AVEO’s Included Lung Cancer Pipeline and Competitive Fall-Out 951
Table 97: Avila Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 952
Table 98: Axelar’s Included Lung Cancer Pipeline and Competitive Fall-Out 954
Table 99: Bayer’s Included Lung Cancer Pipeline and Competitive Fall-Out 955
Table 100: Benitec’s Included Lung Cancer Pipeline and Competitive Fall-Out 959
Table 101: Betapharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 960
Table 102: Biogen Idec’s Included Lung Cancer Pipeline and Competitive Fall-Out 962
Table 103: Biokine Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 965
Table 104: BioLineRx’s Included Lung Cancer Pipeline and Competitive Fall-Out 966
Table 105: BioNumerik’s Included Lung Cancer Pipeline and Competitive Fall-Out 967
Table 106: BioSante’s Included Lung Cancer Pipeline and Competitive Fall-Out 969
Table 107: Boehringer Ingelheim’s Included Lung Cancer Pipeline and Competitive Fall-Out 970
Table 108: Bristol-Myers Squibb’s Included Lung Cancer Pipeline and Competitive Fall-Out 973
Table 109: BTG’s Included Lung Cancer Pipeline and Competitive Fall-Out 984
Table 110: Calando Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 986
Table 111: CanBas’Included Lung Cancer Pipeline and Competitive Fall-Out 987
Table 112: Celator Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 988
Table 113: Celgene’s Included Lung Cancer Pipeline and Competitive Fall-Out 990
Table 114: Cell Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 993
Table 115: Celtic Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 996
Table 116: Center of Molecular Immunology’s Included Lung Cancer Pipeline and Competitive Fall-Out 997
Table 117: Cephalon’s Included Lung Cancer Pipeline and Competitive Fall-Out 999
Table 118: CG Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1002
Table 119: Chemokine Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1003
Table 120: Chong Kun Dang’s Included Lung Cancer Pipeline and Competitive Fall-Out 1004
Table 121: Circadian Technologies’Included Lung Cancer Pipeline and Competitive Fall-Out 1007
Table 122: Clavis Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1008
Table 123: CLL Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1009
Table 124: Coronado Biosciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1012
Table 125: Critical Outcome Technologies’Included Lung Cancer Pipeline and Competitive Fall-Out 1014
Table 126: Curaxis’Included Lung Cancer Pipeline and Competitive Fall-Out 1015
Table 127: Curis’Included Lung Cancer Pipeline and Competitive Fall-Out 1016
Table 128: Cyclacel’s Included Lung Cancer Pipeline and Competitive Fall-Out 1018
Table 129: Cynvec’s Included Lung Cancer Pipeline and Competitive Fall-Out 1019
Table 130: CytImmune Sciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1020
Table 131: Cytokinetics’Included Lung Cancer Pipeline and Competitive Fall-Out 1021
Table 132: CytRx’s Included Lung Cancer Pipeline and Competitive Fall-Out 1023
Table 133: Daiichi Sankyo’s Included Lung Cancer Pipeline and Competitive Fall-Out 1025
Table 134: Dainippon Sumitomo Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1030
Table 135: Dara Biosciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1033
Table 136: Dendreon’s Included Lung Cancer Pipeline and Competitive Fall-Out 1034
Table 137: Dong-A’s Included Lung Cancer Pipeline and Competitive Fall-Out 1036
Table 138: ECI’s Included Lung Cancer Pipeline and Competitive Fall-Out 1038
Table 139: Eisai’s Included Lung Cancer Pipeline and Competitive Fall-Out 1039
Table 140: Elara Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1043
Table 141: Eli Lilly’s Included Lung Cancer Pipeline and Competitive Fall-Out 1046
Table 142: Endocyte’s Included Lung Cancer Pipeline and Competitive Fall-Out 1052
Table 143: EntreMed’s Included Lung Cancer Pipeline and Competitive Fall-Out 1054
Table 144: EpiCept’s Included Lung Cancer Pipeline and Competitive Fall-Out 1055
Table 145: Exelixis’Included Lung Cancer Pipeline and Competitive Fall-Out 1057
Table 146: Fresenius’Included Lung Cancer Pipeline and Competitive Fall-Out 1062
Table 147: Galapagos’Included Lung Cancer Pipeline and Competitive Fall-Out 1064
Table 148: Gemin X Biotechnologies’Included Lung Cancer Pipeline and Competitive Fall-Out 1065
Table 149: Genmab’s Included Lung Cancer Pipeline and Competitive Fall-Out 1066
Table 150: Genta’s Included Lung Cancer Pipeline and Competitive Fall-Out 1068
Table 151: GenVec’s Included Lung Cancer Pipeline and Competitive Fall-Out 1069
Table 152: Genzyme’s Included Lung Cancer Pipeline and Competitive Fall-Out 1070
Table 153: Geron’s Included Lung Cancer Pipeline and Competitive Fall-Out 1071
Table 154: Gilead Sciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1073
Table 155: GlaxoSmithKline’s Included Lung Cancer Pipeline and Competitive Fall-Out 1075
Table 156: GlobeImmune’s Included Lung Cancer Pipeline and Competitive Fall-Out 1079
Table 157: GlycoGenesys’Included Lung Cancer Pipeline and Competitive Fall-Out 1080
Table 158: Gradalis’Included Lung Cancer Pipeline and Competitive Fall-Out 1081
Table 159: Hanmi’s Included Lung Cancer Pipeline and Competitive Fall-Out 1082
Table 160: Hoffmann-La Roche’s Included Lung Cancer Pipeline and Competitive Fall-Out 1083
Table 161: Human Genome Sciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1091
Table 162: Idera Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1092
Table 163: ImmunoCellular Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1093
Table 164: Immunocore’s Included Lung Cancer Pipeline and Competitive Fall-Out 1094
Table 165: ImmunoGen’s Included Lung Cancer Pipeline and Competitive Fall-Out 1096
Table 166: Immunomedics’Included Lung Cancer Pipeline and Competitive Fall-Out 1099
Table 167: ImmuPharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1103
Table 168: Incyte Corporation’s Included Lung Cancer Pipeline and Competitive Fall-Out 1104
Table 169: Infinity Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1105
Table 170: Innovive’s Included Lung Cancer Pipeline and Competitive Fall-Out 1106
Table 171: Inovio’s Included Lung Cancer Pipeline and Competitive Fall-Out 1107
Table 172: Insys Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1108
Table 173: Intezyne Technologies’Included Lung Cancer Pipeline and Competitive Fall-Out 1111
Table 174: Introgen Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1113
Table 175: Ipsen’s Included Lung Cancer Pipeline and Competitive Fall-Out 1115
Table 176: Isis Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1117
Table 177: Jennerex Biotherapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1119
Table 178: Johnson & Johnson’s Included Lung Cancer Pipeline and Competitive Fall-Out 1120
Table 179: Kiadis’Included Lung Cancer Pipeline and Competitive Fall-Out 1123
Table 180: Kyowa Hakko Kirin’s Included Lung Cancer Pipeline and Competitive Fall-Out 1124
Table 181: Ligand’s Included Lung Cancer Pipeline and Competitive Fall-Out 1128
Table 182: Lorus Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1129
Table 183: MacroGenics’Included Lung Cancer Pipeline and Competitive Fall-Out 1131
Table 184: Marillion Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1132
Table 185: Meda’s Included Lung Cancer Pipeline and Competitive Fall-Out 1133
Table 186: MediGene’s Included Lung Cancer Pipeline and Competitive Fall-Out 1134
Table 187: Medisyn Technologies’Included Lung Cancer Pipeline and Competitive Fall-Out 1136
Table 188: Menarini’s Included Lung Cancer Pipeline and Competitive Fall-Out 1138
Table 189: Merck & Co’s Included Lung Cancer Pipeline and Competitive Fall-Out 1140
Table 190: Merck KGaA’s Included Lung Cancer Pipeline and Competitive Fall-Out 1143
Table 191: Merrimack’s Included Lung Cancer Pipeline and Competitive Fall-Out 1147
Table 192: Mersana Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1148
Table 193: MethylGene’s Included Lung Cancer Pipeline and Competitive Fall-Out 1150
Table 194: Micromet’s Included Lung Cancer Pipeline and Competitive Fall-Out 1152
Table 195: Mirna Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1154
Table 196: MolMed’s Included Lung Cancer Pipeline and Competitive Fall-Out 1155
Table 197: Mologen’s Included Lung Cancer Pipeline and Competitive Fall-Out 1157
Table 198: Mycenax’s Included Lung Cancer Pipeline and Competitive Fall-Out 1159
Table 199: Nektar Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1160
Table 200: Nereus Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1162
Table 201: Nerviano Medical Sciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1163
Table 202: Neurocrine Biosciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1165
Table 203: NewSouth Innovations’Included Lung Cancer Pipeline and Competitive Fall-Out 1166
Table 204: Nippon Kayaku’s Included Lung Cancer Pipeline and Competitive Fall-Out 1167
Table 205: Nippon Shinyaku’s Included Lung Cancer Pipeline and Competitive Fall-Out 1169
Table 206: Non-industrial source’s Included Lung Cancer Pipeline and Competitive Fall-Out 1170
Table 207: Novacea’s Included Lung Cancer Pipeline and Competitive Fall-Out 1171
Table 208: Novartis’Included Lung Cancer Pipeline and Competitive Fall-Out 1172
Table 209: Oasmia’s Included Lung Cancer Pipeline and Competitive Fall-Out 1178
Table 210: OncoGenex Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1180
Table 211: OncoMed’s Included Lung Cancer Pipeline and Competitive Fall-Out 1182
Table 212: Oncothyreon’s Included Lung Cancer Pipeline and Competitive Fall-Out 1183
Table 213: Orchestra Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1185
Table 214: OSI Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1186
Table 215: OXiGENE’s Included Lung Cancer Pipeline and Competitive Fall-Out 1189
Table 216: Paladin Labs’Included Lung Cancer Pipeline and Competitive Fall-Out 1190
Table 217: PanaGin’s Included Lung Cancer Pipeline and Competitive Fall-Out 1191
Table 218: PBL Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1192
Table 219: Pfizer’s Included Lung Cancer Pipeline and Competitive Fall-Out 1193
Table 220: Pharmacyclics’Included Lung Cancer Pipeline and Competitive Fall-Out 1202
Table 221: PharmaGap’s Included Lung Cancer Pipeline and Competitive Fall-Out 1203
Table 222: PharmaMar’s Included Lung Cancer Pipeline and Competitive Fall-Out 1204
Table 223: Pharmexa’s Included Lung Cancer Pipeline and Competitive Fall-Out 1207
Table 224: Philogen’s Included Lung Cancer Pipeline and Competitive Fall-Out 1208
Table 225: Pierre Fabre’s Included Lung Cancer Pipeline and Competitive Fall-Out 1210
Table 226: Pro-Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1211
Table 227: Progen Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1212
Table 228: Receptor BioLogix’s Included Lung Cancer Pipeline and Competitive Fall-Out 1213
Table 229: Regeneron’s Included Lung Cancer Pipeline and Competitive Fall-Out 1214
Table 230: Regulon’s Included Lung Cancer Pipeline and Competitive Fall-Out 1215
Table 231: RESprotect’s Included Lung Cancer Pipeline and Competitive Fall-Out 1216
Table 232: Rexahn’s Included Lung Cancer Pipeline and Competitive Fall-Out 1217
Table 233: Rigel’s Included Lung Cancer Pipeline and Competitive Fall-Out 1219
Table 234: Samyang’s Included Lung Cancer Pipeline and Competitive Fall-Out 1221
Table 235: Sanofi-Aventis’Included Lung Cancer Pipeline and Competitive Fall-Out 1225
Table 236: Sareum’s Included Lung Cancer Pipeline and Competitive Fall-Out 1229
Table 237: Seattle Genetics’Included Lung Cancer Pipeline and Competitive Fall-Out 1231
Table 238: ShimodaAtlantic Oncology’s Included Lung Cancer Pipeline and Competitive Fall-Out 1232
Table 239: Shire’s Included Lung Cancer Pipeline and Competitive Fall-Out 1233
Table 240: Sigma-Tau’s Included Lung Cancer Pipeline and Competitive Fall-Out 1234
Table 241: Silence Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1236
Table 242: Simcere Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1237
Table 243: Sirnaomics’Included Lung Cancer Pipeline and Competitive Fall-Out 1238
Table 244: SRI International’s Included Lung Cancer Pipeline and Competitive Fall-Out 1239
Table 245: SuperGen’s Included Lung Cancer Pipeline and Competitive Fall-Out 1240
Table 246: Supratek Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1243
Table 247: Switch Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1247
Table 248: Symphogen’s Included Lung Cancer Pipeline and Competitive Fall-Out 1248
Table 249: SynDevRx’s Included Lung Cancer Pipeline and Competitive Fall-Out 1249
Table 250: Synta Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1251
Table 251: Taiho’s Included Lung Cancer Pipeline and Competitive Fall-Out 1252
Table 252: Takeda’s Included Lung Cancer Pipeline and Competitive Fall-Out 1254
Table 253: Talon Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1256
Table 254: Tapestry Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1257
Table 255: Taxolog’s Included Lung Cancer Pipeline and Competitive Fall-Out 1259
Table 256: Tekmira Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1262
Table 257: Telik’s Included Lung Cancer Pipeline and Competitive Fall-Out 1264
Table 258: Thallion Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1265
Table 259: Therion Biologics’Included Lung Cancer Pipeline and Competitive Fall-Out 1266
Table 260: Theryte’s Included Lung Cancer Pipeline and Competitive Fall-Out 1267
Table 261: Titan Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1268
Table 262: TopoTarget’s Included Lung Cancer Pipeline and Competitive Fall-Out 1270
Table 263: Tracon Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1271
Table 264: Tragara Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1272
Table 265: Transgene’s Included Lung Cancer Pipeline and Competitive Fall-Out 1273
Table 266: TriAct Therapeutics’Included Lung Cancer Pipeline and Competitive Fall-Out 1275
Table 267: Trion Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1276
Table 268: UCB’s Included Lung Cancer Pipeline and Competitive Fall-Out 1277
Table 269: Valeant’s Included Lung Cancer Pipeline and Competitive Fall-Out 1278
Table 270: Vaxon Biotech’s Included Lung Cancer Pipeline and Competitive Fall-Out 1279
Table 271: VaxOnco’s Included Lung Cancer Pipeline and Competitive Fall-Out 1280
Table 272: Vernalis’Included Lung Cancer Pipeline and Competitive Fall-Out 1281
Table 273: Vertex Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1282
Table 274: Vical’s Included Lung Cancer Pipeline and Competitive Fall-Out 1283
Table 275: Vion Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1284
Table 276: VioQuest Pharmaceuticals’Included Lung Cancer Pipeline and Competitive Fall-Out 1286
Table 277: Wilex’s Included Lung Cancer Pipeline and Competitive Fall-Out 1287
Table 278: Wyeth’s Included Lung Cancer Pipeline and Competitive Fall-Out 1288
Table 279: Xerion’s Included Lung Cancer Pipeline and Competitive Fall-Out 1289
Table 280: Xoma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1291
Table 281: Yakult Honsha’s Included Lung Cancer Pipeline and Competitive Fall-Out 1292
Table 282: YM BioSciences’Included Lung Cancer Pipeline and Competitive Fall-Out 1294
Table 283: Zhejiang Beta Pharma’s Included Lung Cancer Pipeline and Competitive Fall-Out 1296
Table 284: Zivena’s Included Lung Cancer Pipeline and Competitive Fall-Out 1298

This report includes 217 companies plus their collaborators:
A&G Pharmaceutical
Abbott
Active Biotech
Adherex
Advanomics
Advantagene
AEgera
AEterna Zentaris
Agennix
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
AlphaVax
Altor BioScience
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
ApopLogic Pharmaceuticals
Apotex
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
AVEO
Avila Therapeutics
Axelar
Bayer
Benitec
Betapharma
Biogen Idec
Biokine Therapeutics
BioLineRx
BioNumerik
BioSante
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Celator Pharmaceuticals
Celgene
Cell Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Circadian Technologies
Clavis Pharma
CLL Pharma
Coronado Biosciences
Critical Outcome Technologies
Curaxis
Curis
Cyclacel
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
Dong-A
ECI
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
EntreMed
EpiCept
Exelixis
Fresenius
Galapagos
Gemin X Biotechnologies
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Gradalis
Hanmi
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innovive
Inovio
Insys Therapeutics
Intezyne Technologies
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kiadis
Kyowa Hakko Kirin
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
Nippon Kayaku
Nippon Shinyaku
Novacea
Novartis
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Oncothyreon
Orchestra Therapeutics
OSI Pharmaceuticals
OXiGENE
Paladin Labs
PanaGin
PBL Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Progen Pharmaceuticals
Pro-Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Samyang
Sanofi-Aventis
Sareum
Seattle Genetics
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Taxolog
Tekmira Pharmaceuticals
Telik
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
Valeant
Vaxon Biotech
VaxOnco
Vernalis
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Wilex
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zhejiang Beta Pharma
Zivena
This report includes 416 cancer drugs. From Ceased to Marketed. Some examples are:
afatinib
aflibercept
amrubicin hydrochloride
ARQ-197
astuprotimut-r
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
canfosfamide hydrochloride
celecoxib
cetuximab
crizotinib
dacomitinib
docetaxel
emepepimut-S
endostatin
erlotinib
etoposide (1)
etoposide phosphate
gefitinib
icotinib hydrochloride
iniparib
interferon (gamma1b)
irinotecan hydrochloride
lapatinib ditosylate
motesanib diphosphate
nadroparin
necitumumab
nimotuzumab
oblimersen sodium
paclitaxel
paclitaxel polyglumex
pazopanib hydrochloride
pemetrexed disodium
ramucirumab
sorafenib tosylate
talactoferrin alfa
tegafur + uracil
thymalfasin
topotecan
TS-1

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market.
    To find out more about Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Cancer Vaccines: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More

Other selected research from the 'Oncology' category:


GnRH Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 185 companies plus partners who are today developing 234 GnRH signaling pathway targeting drugs in 844 developmental projects in cancer across 126 different targets. In addition, there is 1 suspended drug and another 86 drugs where development has been ceased. Learn More


Lymphoma Drug Pipeline Update
BioSeeker Group have identified 383 companies plus partners who are today developing 568 lymphoma drugs in 1073 developmental projects in cancer across 302 different targets. In addition, there are 4 suspended drugs and another 143 drugs where development has been ceased. Learn More